feb 12, 2018: 3 p.m. - 3:55 p.m.
The tradition of health systems paying for biopharma treatments by the dose gets strained when confronted by the latest therapeutic technologies that may offer multi-year benefits or lifetime relief from disease per a single administration of a highly customized therapy. Finding analogous methods of matching payment schedules to long-duration benefits, while covering up-front costs, shows how unprepared organizations are for the era of delivering access to gene therapies and other potential cures. This session will consider market-based options and identify relevant policy barriers to experimenting with amortization models and other techniques for funding non-traditional treatments that could greatly improve or extend patients’ lives.
Moderator: Brady Huggett, Business Editor, Nature Biotechnology
Ted Haack, Vice President, LatticePoint Consulting
Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital
Michael B. Weiss, Partner, Cahill Gordon & Reindel LLP
Michael J. Werner, Partner, Holland & Knight LLP, Co-Founder & Senior Policy Counsel, Alliance for Regenerative Medicine